Clinical-stage biopharmaceutical company Kythera Biopharmaceuticals has reported positive interim results from a multi-centre, open-label Phase IIIb study of its investigational injectable drug for the reduction of unwanted submental fat (SMF), known as double chin.

ATX-101, a proprietary formulation of endogenous synthetic deoxycholic acid, is injected locally to cause proximal, preferential destruction of adipocytes, or fat cells, with minimal effect on surrounding tissue.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The study, which has treated more than 1,500 patients from a total of 2,500 enrolled patients, was designed to study the safety and efficacy of ATX-101 in reducing SMF.

"ATX-101, a proprietary formulation of endogenous synthetic deoxycholic acid, is injected locally to cause proximal, preferential destruction of adipocytes, or fat cells, with minimal effect on surrounding tissue."

The results of three months after the last ATX-101 treatment found that 87% of patients achieved at least a one-grade improvement from baseline on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS), while 83% achieved at least a one-grade improvement on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS).

96% percent of patients had unchanged or improved skin laxity based on the clinician-rated Submental Skin Laxity Grading Scale (SMSLG), while 95% were satisfied with treatment based on the Global Post Treatment Satisfaction Scale.

See Also:

In addition, adverse events were of mild to moderate intensity, transient and primarily associated with the treatment area.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

University of South Florida board certified dermatologist and affiliate clinical professor and trial investigator Dr Susan Weinkle said; "The results of this study suggest that microinjections of ATX-101 can reduce submental fat without worsening skin laxity."

The company also announced study topline results, as announced in November 2012, which found out that 71.3% of subjects had at least a one-grade improvement on the CR-SMFRS / PR-SMFRS composite and 14% had at least a two-grade improvement on the same composite measure.

Kythera Biopharmaceuticals chief medical officer Dr Patricia Walker said; "These results, along with efficacy analyses in double-blind, placebo-controlled studies, support ATX-101 entering the market as potentially the first medical aesthetic drug approved for the reduction of submental fat."